Cargando…
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
CONTEXT: We examined if empagliflozin was associated with modulation of cardiac autonomic tone among subjects with type 2 diabetes and stable coronary artery disease (CAD) relative to placebo. METHODS: Using ambulatory 24-h Holter electrocardiographic data prospectively collected from a randomized t...
Autores principales: | Garg, Vinay, Verma, Subodh, Connelly, Kim A., Yan, Andrew T., Sikand, Aditya, Garg, Ankit, Dorian, Paul, Zuo, Fei, Leiter, Lawrence A., Zinman, Bernard, Jüni, Peter, Verma, Atul, Teoh, Hwee, Quan, Adrian, Mazer, C. David, Ha, Andrew C.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424781/ https://www.ncbi.nlm.nih.gov/pubmed/32812924 http://dx.doi.org/10.1016/j.metop.2020.100039 |
Ejemplares similares
-
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023) -
IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023) -
Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial
por: Garg, Vinay, et al.
Publicado: (2017) -
Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial)
por: Chan, Vincent, et al.
Publicado: (2017) -
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)